期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 18, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/ijms18071345
关键词
bone targeting drugs; osteoporosis; metabolic skeletal dysplasia; bisphosphonates; nanoparticles
资金
- International Morquio Organization (Carol Ann Foundation)
- Japanese Mucopolysaccharidosis Family Society
- Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of NIH [P30GM114736]
- Austrian Mucopolysaccharidosis Society
The skeletal system, comprising bones, ligaments, cartilage and their connective tissues, is critical for the structure and support of the body. Diseases that affect the skeletal system can be difficult to treat, mainly because of the avascular cartilage region. Targeting drugs to the site of action can not only increase efficacy but also reduce toxicity. Bone-targeting drugs are designed with either of two general targeting moieties, aimed at the entire skeletal system or a specific cell type. Most bone-targeting drugs utilize an affinity to hydroxyapatite, a major component of the bone matrix that includes a high concentration of positively-charged Ca2+. The strategies for designing such targeting moieties can involve synthetic and/or biological components including negatively-charged amino acid peptides or bisphosphonates. Efficient delivery of bone-specific drugs provides significant impact in the treatment of skeletal related disorders including infectious diseases (osteoarthritis, osteomyelitis, etc.), osteoporosis, and metabolic skeletal dysplasia. Despite recent advances, however, both delivering the drug to its target without losing activity and avoiding adverse local effects remain a challenge. In this review, we investigate the current development of bone-targeting moieties, their efficacy and limitations, and discuss future directions for the development of these specific targeted treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据